Remission

BOSTON — Targeting asthma remission as the next goal in asthma therapy should be prioritized, according to a presentation at the CHEST Annual Meeting.

Patients with severe Behçet’s syndrome who received infliximab demonstrated better odds of achieving complete response at 22 weeks compared with those who used cyclophosphamide, according to head-to-head data published in NEJM Evidence.

Long-term filgotinib induced and maintained symptomatic remission and improved health-related quality of life in ulcerative colitis, with no new safety signals reported, according to interim analysis of the SELECTION extension study.

SAN ANTONIO — Clinicians and researchers are beginning to explore whether asthma remission is possible, Corinne Young, FNP-C, FCCP, said during her presentation at the 16th Annual Allergy, Asthma & Immunology CME Conference.

For patients with chronic periprosthetic joint infection, multistage revision total knee arthroplasty procedures were associated with high remission rates and low mortality at minimum 5-year follow-up, according to published results.

Nearly half of patients with gout achieved remission with pegloticase treatment by 52 weeks, indicating longer-term benefits for intensive urate-lowering therapy, according to data presented at EULAR 2024 Congress.

New definitions of remission specific to childhood systemic lupus erythematosus promote cessation of corticosteroids and could enable combined child-adult treat-to-target studies, according to an analysis published in Clinical Immunology.